Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Antimicrobial dual-crosslinked hydrogel synergizes bioengineered extracellular vesicles for enhanced diabetic wound healing.

Ju Y., Yang P., Liu X., Wu R., Shen N., Hsiung N.

Animal Study on Diabetic Foot, Chronic Wound, published in Mater Today Bio (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mater Today Bio (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40487175
PMCID
PMC12145714
DOI
10.1016/j.mtbio.2025.101870
Citations
4

Abstract (original English)

Diabetic wound healing remains a major clinical challenge owing to impaired angiogenesis, prolonged inflammation, and bacterial infection. Stem cell-derived extracellular vesicles (EVs) offer a promising solution for improving diabetic wound healing. The biological activity of EVs can be increased by engineering modifications. Antimicrobial hydrogel dressings combined with bioengineered EVs, will provide a good solution to the problem of difficult healing of diabetic wounds. Therefore, this study aims to investigate the potential of BCL-2 -engineered EVs to enhance wound healing in a diabetic mouse model. BCL-2 engineered adipose mesenchymal stem cells were constructed using the lentiviral embedding method, and analyzed their transcriptional changes through transcriptome sequencing. Their secreted EVs were isolated and characterized by proteomic sequencing. Integrating bioinformatics analysis, we found that BCL-2 engineered EVs may play a powerful role in angiogenesis and tissue repair. Furthermore, we developed an antimicrobial hydrogel based on epsilon-poly-lysine and hyaluronic acid to encapsulate them. The hydrogel-EVs system demonstrated a comprehensive promotion of wound healing, including increased angiogenesis, enhanced cell proliferation, reduced inflammation, and improved tissue architecture. These findings highlighted the potential of BCL-2 -engineered EV-loaded anti

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research